Pro-Dex, Inc. reported significant financial growth in its fiscal year ending June 30, 2025, with net sales reaching $66.6 million, a 24% increase from $53.8 million in the previous year. The company's gross profit also rose to $19.5 million, representing a gross margin of 29%, compared to 27% in fiscal 2024. This growth was primarily driven by a $10.8 million increase in medical device revenue, which accounted for 72% of total sales, and a $2.1 million rise in repair revenue. The company’s operating income improved to $10.7 million, up from $7.2 million in the prior year, while net income surged to $9.0 million, compared to $2.1 million in fiscal 2024.
Pro-Dex's customer concentration increased, with its top three customers accounting for 94% of total sales in fiscal 2025, up from 88% in the previous year. Notably, one customer represented 75% of total sales, a significant rise from 71% in fiscal 2024. The company has maintained strong relationships with these key customers, which are crucial for its revenue stability. Additionally, Pro-Dex's backlog of orders grew substantially to $50.4 million at the end of fiscal 2025, compared to $19.8 million a year earlier, indicating strong demand for its products.
Operationally, Pro-Dex has made strategic investments to enhance its capacity and efficiency. The company completed the build-out of its new facility in Tustin, California, which is expected to support future growth. The workforce also expanded, with employee headcount increasing to 181 from 148 in the previous year. The company continues to focus on research and development, investing $3.6 million in fiscal 2025, which is essential for maintaining its competitive edge in the medical device market.
Despite the positive financial performance, Pro-Dex faces challenges, including increased costs from suppliers and potential impacts from tariffs. The company has noted that some suppliers have begun passing along tariff charges, which could affect profit margins. Additionally, the competitive landscape remains intense, with several competitors possessing greater resources. Pro-Dex's management remains optimistic about future growth, emphasizing ongoing product development and customer engagement as key strategies to navigate these challenges.
Looking ahead, Pro-Dex anticipates continued revenue growth driven by its expanding product offerings and strong customer relationships. The company plans to leverage its increased operational capacity and backlog to meet anticipated demand in fiscal 2026. However, management acknowledges the inherent risks associated with customer concentration and market competition, which could impact future performance.
About PRO DEX INC
Pro-Dex, Inc. designs and manufactures autoclavable, battery-powered surgical drivers and shavers for the medical industry, primarily serving orthopedic, thoracic, and craniomaxillofacial markets. It offers proprietary torque-limiting technology, custom device development, and repair services. The company supplies OEMs and distributors, emphasizing innovation, regulatory compliance, and capacity expansion to support growth in a competitive, technology-driven healthcare sector.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.